FDA Approves OXCARBAZEPINE — Novadoz Pharmaceuticals LLC
Novadoz Pharmaceuticals announced the FDA approval of its oral oxcarbazepine tablets (ANDA 209020), a generic version of the anticonvulsant, which is expected to bolster the company’s sales pipeline and introduce a new revenue stream by May 29, 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day